GlassScriptPhysician profile
Swapna Thota
NPI 1821301052
$42,008.60
in general payments reported to CMS, 2019-2025
35 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $3,555 · 2021: $875 · 2022: $6,864 · 2023: $7,880 · 2024: $9,308 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $2,295 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,106.00 |
| Food and Beverage | $2,294.65 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,153.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $13,303.03 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $6,831.56 | 2021-2025 | |
| Blueprint Medicines Corporation | $5,251.68 | 2020-2023 | Ayvakit |
| Pharmaessentia USA Corporation | $5,220.00 | 2024 | Besremi |
| Alexion Pharmaceuticals, INC. | $4,229.89 | 2022-2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $2,474.26 | 2022-2025 | Breyanzi |
| Daiichi Sankyo INC. | $1,561.32 | 2023-2025 | Vanflyta, Enhertu |
| Celgene Corporation | $1,142.80 | 2023-2025 | Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $278.85 | 2021-2025 | |
| Pfizer INC. | $254.59 | 2022-2025 | |
| Amgen INC. | $179.00 | 2021-2023 | Blincyto, Kyprolis |
| Astellas Pharma US INC | $115.08 | 2019-2025 | Vyloy |
| Abbvie INC. | $108.45 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $100.54 | 2024-2025 | Keytruda, Welireg |
| Sobi, INC | $100.51 | 2024-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $99.55 | 2023 | Rylaze |
| Adaptive Biotechnologies Corporation | $95.05 | 2021-2024 | Clonoseq |
| Acrotech Biopharma INC. | $91.55 | 2024 | Beleodaq |
| Genzyme Corporation | $68.00 | 2024 | |
| Beigene USA, INC. | $51.61 | 2024-2025 | Brukinsa |
| Apellis Pharmaceuticals, INC. | $49.06 | 2023 | Empaveli |
| Janssen Pharmaceuticals, INC | $48.84 | 2022-2023 | Xarelto |
| Karyopharm Therapeutics INC. | $44.09 | 2022-2025 | Xpovio |
| Janssen Biotech, INC. | $42.82 | 2024-2025 | Erleada, Balversa, Tecvayli |
| Alnylam Pharmaceuticals INC. | $33.51 | 2025 | Givlaari |
| Eisai INC. | $33.44 | 2025 | |
| Azurity Pharmaceuticals, INC. | $28.39 | 2024 | Triptodur |
| Glaxosmithkline, LLC. | $27.82 | 2025 | Zejula, Jemperli |
| Recordati_rare_diseases_inc. | $27.33 | 2025 | Enjaymo |
| Syndax Pharmaceuticals, INC. | $22.18 | 2025 | |
| Integra Lifesciences Corporation | $20.57 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Lilly USA, LLC | $20.21 | 2024 | Verzenio, Jaypirca |
| Seagen INC. | $19.75 | 2021 | |
| G1 Therapeutics, INC. | $17.91 | 2023 | Cosela |
| Kyowa Kirin, INC. | $15.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swapna Thota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.